Motley Fool Australia

Fiji Kava share price explodes 71% after company lands partnership to supply to China

Colourful explosion to symbolise ASX share price growth
Image source: Getty Images

The Fiji Kava Ltd (ASX: FIJ) share price flew higher today and is up by 71.88% at the time of writing to 28 cents. This came after the company announced that it had landed a partnership to supply its medicinal products to China.

What was in the announcement?

According to Fiji Kava, it signed an agreement with PuMate (Shanghai) as its authorised distributor to supply the company’s medicinal products to China. Fiji Kava stated that the landmark agreement includes a minimum sales requirement of $8 million over the initial 3-year term of the agreement.

The agreement is extendable for periods of 12 months each after the initial 3-year term. If PuMate reach a target of $10 million in annual gross revenue, Fiji Kava have agreed to issue the distributor 1.5 million options at a discount of 15% to the 30-day volume weighted average price, subject to shareholder approval.

Fiji Kava stated that the agreement includes diversified distribution channels into China with both branded Fiji Kava products and raw Noble Kava extracts to be sold in China’s complementary medicine, personal care and pharmaceutical industries as well as through e-commerce marketplaces.

Fiji Kava non-executive director Nicholas Simms stated:  “This agreement has been structured in a way that diversifies our revenue streams in China via co-development possibilities with manufacturers of vitamins and supplements in China, and sales of Fiji Kava’s existing product ranges through cross-border eCommerce marketplaces and retail partners.”

According to the announcement, China’s vitamin and supplement market is worth $30 billion per year.

About the Fiji Kava share price

Fiji Kava is an Australian-Fijian company that produces ‘noble kava’ products for the complementary and alternative medicine market. Its products are TGA and FDA compliant. Fiji Kava has been listed on the ASX since 2018.

Earlier this month, Fiji Kava announced that it had signed a major agreement with a subsidiary of Blackmores Limited (ASX: BKL), BioCeuticals. Under the agreement, BioCeuticals will have a licence to add Noble Kava produced by Fiji Kava to its AnxioCalm product.

The Fiji Kava share price is up 865% since its 52-week low of 2.9 cents and up 358% since this time last year.

This Tiny ASX Stock Could Be the Next Afterpay

One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...

Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.

Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!

Returns as of 6th October 2020

Motley Fool contributor Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles…

Latest posts by Chris Chitty (see all)